FINWIRES · TerminalLIVE
FINWIRES

$IRD

7 stories mentioning IRDUpdated 14d ago

Every FINWIRES story that references IRD, newest first.

What are analysts saying about IRD?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on IRD?

Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Wednesday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.2%.The iShares Biotechnology ETF (IBB) declined 0.8%.In corporate news, UnitedHealth (UNH) sold an interest in some of its Optum Health operations in Florida to TPG (TPG), Bloomberg reported. UnitedHealth shares were down 2.2%.Agilent Technologies (A) shares fell 1.2% after UBS downgraded the stock to neutral from buy.Rezolute (RZLT) said Wednesday that the US Food and Drug Administration is still reviewing data from a phase 3 study of ersodetug for the potential treatment of hypoglycemia due to congenital hyperinsulinism. The company said it does not have a specific timeline on when it will receive feedback or guidance from the FDA on potential next steps. Rezolute shares were down past 7%.Opus Genetics (IRD) shares jumped 35% after it said that patients with Bestrophin-1-related retinal diseases showed clinically meaningful improvement in visual function in the low-dose cohort 1 of its BIRD-1 phase 1/2 trial evaluating OPGx-BEST1.

$A$IRD$RZLT$UNH
Wire

Update: Opus Genetics Shares Rise After Reporting Vision Improvement in Phase 1/2 OPGx-BEST1 Trial

(Updates to add share movement in first paragraph and headline)Opus Genetics (IRD) shares jumped 30% in Wednesday trading after it said that patients with Bestrophin-1-related retinal diseases showed clinically meaningful improvement in visual function in the low-dose cohort 1 of its BIRD-1 phase 1/2 clinical trial evaluating OPGx-BEST1.The biopharmaceutical company said the five participants in the trial with BEST1-related retinal diseases showed meaningful visual improvements. It also said four of the five patients showed structural improvements.There were no serious adverse events, dose-limiting toxicities, or intraocular inflammation reported in the trial.Price: $5.79, Change: $+1.45, Percent Change: +33.29%

$IRD
Wire

Wedbush Raises Opus Genetics Price Target to $13 From $10, Maintains Outperform Rating

Opus Genetics (IRD) has an average rating of buy and mean price target of $10.71, according to analysts polled by FactSet.Price: $5.68, Change: $+1.34, Percent Change: +30.83%

$IRD
Research

TD Cowen Initiates Opus Genetics at Buy

Opus Genetics (IRD) has an average rating of buy and mean price target of $10.65, according to analysts polled by FactSet.

$IRD
Research

Guggenheim Initiates Opus Genetics at Buy With $16 Price Target

Opus Genetics (IRD) has an average rating of buy and mean price target of $10.27, according to analysts polled by FactSet.

$IRD
Research

Leerink Partners Initiates Opus Genetics at Outperform With $10 Price Target

Opus Genetics, Inc. (IRD) has an average rating of buy and mean price target of $10.27, according to analysts polled by FactSet.

$IRD
Wire

B. Riley Adjusts Opus Genetics Price Target to $10 From $9, Maintains Buy Rating

B. Riley Adjusts Opus Genetics Price Target to $10 From $9, Maintains Buy Rating

$IRD

Track with the FINWIRES app suite